DPP4 as a Potential Candidate in Cardiovascular Disease

References

• Teo KK, Rafiq T. Cardiovascular risk factors and prevention: a perspective from developing countries. Can J Cardiol. 2021;37(5):733–743. doi:10.1016/j.cjca.2021.02.009
   PubMed Web of Science ®Google Scholar
• Fuchs FD, Whelton PK. High blood pressure and cardiovascular disease. Hypertension. 2020;75(2):285–292.
   PubMed Web of Science ®Google Scholar
• Mendoza-Vasconez AS, Landry MJ, Crimarco A, Bladier C, Gardner CD. Sustainable diets for cardiovascular disease prevention and management. Curr Atheroscler Rep. 2021;23(7):31.
   PubMed Web of Science ®Google Scholar
• Nasykhova YA, Tonyan ZN, Mikhailova AA, Danilova MM, Glotov AS. Pharmacogenetics of type 2 diabetes-progress and prospects. Int J Mol Sci. 2020;21(18):6842.
   PubMed Web of Science ®Google Scholar
• White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–1335.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–1326.
   PubMed Web of Science ®Google Scholar
• Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–242.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA. 2019;321(1):69–79.
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Kahn SE, Johansen OE, et al. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. JAMA. 2019;322(12):1155–1166.
   PubMed Web of Science ®Google Scholar
• Subrahmanyan NA. Efficacy and Cardiovascular Safety of DPP-4 Inhibitors. Curr Drug Saf. 2021;16(2):154–164. doi:10.2174/22123911MTA5lMzAg0
   PubMed Web of Science ®Google Scholar
• Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular actions and clinical outcomes with glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. Circulation. 2017;136(9):849–870.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Cardiovascular effects of new oral glucose-lowering agents: DPP-4 and SGLT-2 Inhibitors. Circ Res. 2018;122(10):1439–1459.
   PubMed Web of Science ®Google Scholar
• Huang J, Liu X, Wei Y, et al. Emerging role of dipeptidyl peptidase-4 in autoimmune disease. Front Immunol. 2022;13:830863.
   PubMed Web of Science ®Google Scholar
• Enz N, Vliegen G, De Meester I, Jungraithmayr W. CD26/DPP4 - A potential biomarker and target for cancer therapy. Pharmacol Ther. 2019;198:135–159.
   PubMed Web of Science ®Google Scholar
• Love KM, Liu Z. DPP4 activity, hyperinsulinemia, and atherosclerosis. J Clin Endocrinol Metab. 2021;106(6):1553–1565.
   PubMed Web of Science ®Google Scholar
• Klemann C, Wagner L, Stephan M, von Hörsten S. Cut to the chase: a review of CD26/dipeptidyl peptidase-4’s (DPP4) entanglement in the immune system. Clin Exp Immunol. 2016;185(1):1–21.
   PubMed Web of Science ®Google Scholar
• Govender Y, Shalekoff S, Ebrahim O, et al. Systemic DPP4/CD26 is associated with natural HIV-1 control: implications for COVID-19 susceptibility. Clin Immunol. 2021;230:108824.
   PubMed Web of Science ®Google Scholar
• Zhang T, Tong X, Zhang S, et al. The roles of dipeptidyl peptidase 4 (DPP4) and DPP4 inhibitors in different lung diseases: new evidence. Front Pharmacol. 2021;12:731453.
   PubMed Web of Science ®Google Scholar
• Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–1705.
   PubMed Web of Science ®Google Scholar
• Gong Q, Rajagopalan S, Zhong J. Dpp4 inhibition as a therapeutic strategy in cardiometabolic disease: incretin-dependent and -independent function. Int J Cardiol. 2015;197:170–179.
   PubMed Web of Science ®Google Scholar
• Morimoto C, Schlossman SF. The structure and function of CD26 in the T-cell immune response. Immunol Rev. 1998;161:55–70.
   PubMed Web of Science ®Google Scholar
• Sueyoshi R, Miyahara K, Nakazawa-Tanaka N, Fujiwara N, Ochi T, Yamataka A. DPP4 inhibitor reinforces cell junction proteins in mouse model of short bowel syndrome. Pediatr Surg Int. 2020;36(1):49–55.
   PubMed Web of Science ®Google Scholar
• Nistala R, Savin V. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol. 2017;312(4):F661–F670.
   PubMed Web of Science ®Google Scholar
• Nargis T, Chakrabarti P. Significance of circulatory DPP4 activity in metabolic diseases. IUBMB Life. 2018;70(2):112–119.
   PubMed Web of Science ®Google Scholar
• Lee DS, Lee ES, Alam MM, et al. Soluble DPP-4 up-regulates toll-like receptors and augments inflammatory reactions, which are ameliorated by vildagliptin or mannose-6-phosphate. Metabolism. 2016;65(2):89–101.
   PubMed Web of Science ®Google Scholar
• Casrouge A, Sauer AV, Barreira da Silva R, et al. Lymphocytes are a major source of circulating soluble dipeptidyl peptidase 4. Clin Exp Immunol. 2018;194(2):166–179.
   PubMed Web of Science ®Google Scholar
• Deacon CF. Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus. Nat Rev Endocrinol. 2020;16(11):642–653.
   PubMed Web of Science ®Google Scholar
• Mulvihill EE, Drucker DJ. Pharmacology, physiology, and mechanisms of action of dipeptidyl peptidase-4 inhibitors. Endocr Rev. 2014;35(6):992–1019.
   PubMed Web of Science ®Google Scholar
• Patel KV, Sarraju A, Neeland IJ, McGuire DK. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 receptor agonists: a review for the general cardiologist. Curr Cardiol Rep. 2020;22(10):105.
   PubMed Web of Science ®Google Scholar
• Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial. Lancet. 2015;385(9982):2067–2076.
   PubMed Web of Science ®Google Scholar
• Williams R, de Vries F, Kothny W, et al. Cardiovascular safety of vildagliptin in patients with type 2 diabetes: a European multi-database, non-interventional post-authorization safety study. Diabetes Obes Metab. 2017;19(10):1473–1478.
   PubMed Web of Science ®Google Scholar
• Crowley MJ, Williams JW, Kosinski AS, D’Alessio DA, Buse JB. Metformin use may moderate the effect of DPP-4 inhibitors on cardiovascular outcomes. Diabetes Care. 2017;40(12):1787–1789.
   PubMed Web of Science ®Google Scholar
• Scheen AJ. Could metformin modulate cardiovascular outcomes differently with DPP-4 inhibitors compared with SGLT2 inhibitors? Diabetes Metab. 2021;47(4):101209.
   PubMed Web of Science ®Google Scholar
• Wang J, Wu HY, Chien KL. Cardioprotective effects of dipeptidyl peptidase-4 inhibitors versus sulfonylureas in addition to metformin: a nationwide cohort study of patients with type 2 diabetes. Diabetes Metab. 2022;48(3):101299.
   PubMed Web of Science ®Google Scholar
• Ou HT, Chang KC, Li CY, Wu JS. Comparative cardiovascular risks of dipeptidyl peptidase 4 inhibitors with other second- and third-line antidiabetic drugs in patients with type 2 diabetes. Br J Clin Pharmacol. 2017;83(7):1556–1570.
   PubMed Web of Science ®Google Scholar
• Matthews DR, Paldánius PM, Proot P, Chiang Y, Stumvoll M, Del Prato S. Glycaemic durability of an early combination therapy with vildagliptin and metformin versus sequential metformin monotherapy in newly diagnosed type 2 diabetes (VERIFY): a 5-year, multicentre, randomised, double-blind trial. Lancet. 2019;394(10208):1519–1529.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44–58.
   PubMed Web of Science ®Google Scholar
• Chen K, Zhuo T, Wang J, Mei Q. Saxagliptin upregulates nesfatin-1 secretion and ameliorates insulin resistance and metabolic profiles in type 2 diabetes mellitus. Metab Syndr Relat Disord. 2018;16(7):336–341.
   PubMed Web of Science ®Google Scholar
• Cha SA, Park YM, Yun JS, et al. A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes. Lipids Health Dis. 2017;16(1):58.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu J, Wong WT, et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60(3):833–841.
   PubMed Web of Science ®Google Scholar
• Choi B, Kim EY, Kim JE, et al. Evogliptin suppresses calcific aortic valve disease by attenuating inflammation, fibrosis, and calcification. Cells. 2021;10(1):57.
   PubMed Web of Science ®Google Scholar
• Xin M, Jin X, Cui X, et al. Dipeptidyl peptidase-4 inhibition prevents vascular aging in mice under chronic stress: modulation of oxidative stress and inflammation. Chem Biol Interact. 2019;314:108842.
   PubMed Web of Science ®Google Scholar
• Xing X, Han Y, Zhou X, et al. Association between DPP4 gene polymorphism and serum lipid levels in Chinese type 2 diabetes individuals. Neuropeptides. 2016;60:1–6.
   PubMed Web of Science ®Google Scholar
• Tsimihodimos V, Elisaf M. Incretins and lipid metabolism. Curr Med Chem. 2018;25(18):2133–2139.
   PubMed Web of Science ®Google Scholar
• Boschmann M, Engeli S, Dobberstein K, et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009;94(3):846–852.
   PubMed Web of Science ®Google Scholar
• Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227–3337.
   PubMed Web of Science ®Google Scholar
• Kivimäki M, Steptoe A. Effects of stress on the development and progression of cardiovascular disease. Nat Rev Cardiol. 2018;15(4):215–229.
   PubMed Web of Science ®Google Scholar
• Lei Y, Yang G, Hu L, et al. Increased dipeptidyl peptidase-4 accelerates diet-related vascular aging and atherosclerosis in ApoE-deficient mice under chronic stress. Int J Cardiol. 2017;243:413–420.
   PubMed Web of Science ®Google Scholar
• Piao L, Zhao G, Zhu E, et al. Chronic psychological stress accelerates vascular senescence and impairs ischemia-induced neovascularization: the role of dipeptidyl peptidase-4/glucagon-like peptide-1-adiponectin axis. J Am Heart Assoc. 2017;6(10):e006421.
   PubMed Web of Science ®Google Scholar
• Wang X, Gu H, Li K, Lin J, Zhu Y, Deng W. DPP4 inhibitor reduces portal hypertension in cirrhotic rats by normalizing arterial hypocontractility. Life Sci. 2021;284:119895.
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhao Q. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: a systematic review and meta-analysis. J Hypertens. 2016;34(2):167–175.
   PubMed Web of Science ®Google Scholar
• Uchii M, Kimoto N, Sakai M, Kitayama T, Kunori S. Glucose-independent renoprotective mechanisms of the tissue dipeptidyl peptidase-4 inhibitor, saxagliptin, in Dahl salt-sensitive hypertensive rats. Eur J Pharmacol. 2016;783:56–63.
   PubMed Web of Science ®Google Scholar
• Tang ST, Su H, Zhang Q, et al. Sitagliptin inhibits endothelin-1 expression in the aortic endothelium of rats with streptozotocin-induced diabetes by suppressing the nuclear factor-κB/IκBα system through the activation of AMP-activated protein kinase. Int J Mol Med. 2016;37(6):1558–1566.
   PubMed Web of Science ®Google Scholar
• Zhang J, Chen Q, Zhong J, Liu C, Zheng B, Gong Q. DPP-4 inhibitors as potential candidates for antihypertensive therapy: improving vascular inflammation and assisting the action of traditional antihypertensive drugs. Front Immunol. 2019;10:1050.
   PubMed Web of Science ®Google Scholar
• Nistala R, Habibi J, Lastra G, et al. Prevention of obesity-induced renal injury in male mice by DPP4 inhibition. Endocrinology. 2014;155(6):2266–2276.
   PubMed Web of Science ®Google Scholar
• Ishibashi Y, Matsui T, Maeda S, Higashimoto Y, Yamagishi S. Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. Cardiovasc Diabetol. 2013;12:125.
   PubMed Web of Science ®Google Scholar
• Jo CH, Kim S, Park JS, Kim GH. Anti-inflammatory action of sitagliptin and linagliptin in doxorubicin nephropathy. Kidney Blood Press Res. 2018;43(3):987–999.
   PubMed Web of Science ®Google Scholar
• Valencia I, Vallejo S, Dongil P, et al. DPP4 promotes human endothelial cell senescence and dysfunction via the PAR2-COX-2-TP axis and NLRP3 inflammasome activation. Hypertension. 2022;79(7):1361–1373.
   PubMed Web of Science ®Google Scholar
• Liu L, Liu J, Tian XY, et al. Uncoupling protein-2 mediates DPP-4 inhibitor-induced restoration of endothelial function in hypertension through reducing oxidative stress. Antioxid Redox Signal. 2014;21(11):1571–1581.
   PubMed Web of Science ®Google Scholar
• Mu L, Wang Z, Ren J, Xiong X, Jin Z, Liu X. Impact of DPP-4 inhibitors on plasma levels of BNP and NT-pro-BNP in type 2 diabetes mellitus. Diabetol Metab Syndr. 2022;14(1):30.
   PubMed Web of Science ®Google Scholar
• Girardi AC, Fukuda LE, Rossoni LV, Malnic G, Rebouças NA. Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. Am J Physiol Renal Physiol. 2008;294(2):F414–F422.
   PubMed Web of Science ®Google Scholar
• Daza-Arnedo R, Rico-Fontalvo JE, Pájaro-Galvis N, et al. Dipeptidyl peptidase-4 inhibitors and diabetic kidney disease: a narrative review. Kidney Med. 2021;3(6):1065–1073.
   PubMedGoogle Scholar
• Nistala R, Meuth AI, Smith C, et al. DPP4 inhibition mitigates ANG II-mediated kidney immune activation and injury in male mice. Am J Physiol Renal Physiol. 2021;320(3):F505–F517.
   PubMed Web of Science ®Google Scholar
• Kawase H, Bando YK, Nishimura K, Aoyama M, Monji A, Murohara T. A dipeptidyl peptidase-4 inhibitor ameliorates hypertensive cardiac remodeling via angiotensin-II/sodium-proton pump exchanger-1 axis. J Mol Cell Cardiol. 2016;98:37–47.
   PubMed Web of Science ®Google Scholar
• Devin JK, Pretorius M, Nian H, Yu C, Billings FTT, Brown NJ. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension. 2014;63(5):951–957.
   PubMed Web of Science ®Google Scholar
• Abouelkheir M, El-Metwally TH. Dipeptidyl peptidase-4 inhibitors can inhibit angiotensin converting enzyme. Eur J Pharmacol. 2019;862:172638.
   PubMed Web of Science ®Google Scholar
• Ramesh N, Mortazavi S, Unniappan S. Nesfatin-1 stimulates glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide secretion from STC-1 cells in vitro. Biochem Biophys Res Commun. 2015;462(2):124–130.
   PubMed Web of Science ®Google Scholar
• Goody PR, Hosen MR, Christmann D, et al. Aortic valve stenosis: from basic mechanisms to novel therapeutic targets. Arterioscler Thromb Vasc Biol. 2020;40(4):885–900.
   PubMed Web of Science ®Google Scholar
• Lee S, Lee SA, Choi B, et al. Dipeptidyl peptidase-4 inhibition to prevent progression of calcific aortic stenosis. Heart. 2020;106(23):1824–1831.
   PubMed Web of Science ®Google Scholar
• Fernández-Ruiz I. Valvular disease: DPP4 inhibitors to prevent aortic valve calcification. Nat Rev Cardiol. 2017;14(4):190.
   Google Scholar
• Choi B, Lee S, Kim SM, et al. Dipeptidyl peptidase-4 induces aortic valve calcification by inhibiting insulin-like growth factor-1 signaling in valvular interstitial cells. Circulation. 2017;135(20):1935–1950.
   PubMed Web of Science ®Google Scholar
• Salim HM, Fukuda D, Higashikuni Y, et al. Dipeptidyl peptidase-4 inhibitor, linagliptin, ameliorates endothelial dysfunction and atherogenesis in normoglycemic apolipoprotein-E deficient mice. Vascul Pharmacol. 2016;79:16–23.
   PubMed Web of Science ®Google Scholar
• Li B, Luo YR, Tian F, et al. Sitagliptin attenuates the progression of coronary atherosclerosis in patients with coronary disease and type 2 diabetes. Atherosclerosis. 2020;300:10–18.
   PubMed Web of Science ®Google Scholar
• Jebari-Benslaiman S, Galicia-García U, Larrea-Sebal A, et al. Pathophysiology of atherosclerosis. Int J Mol Sci. 2022;23(6):3346.
   PubMed Web of Science ®Google Scholar
• Liu H, Xiang H, Zhao S, et al. Vildagliptin improves high glucose-induced endothelial mitochondrial dysfunction via inhibiting mitochondrial fission. J Cell Mol Med. 2019;23(2):798–810.
   PubMed Web of Science ®Google Scholar
• Hwang HJ, Chung HS, Jung TW, et al. The dipeptidyl peptidase-IV inhibitor inhibits the expression of vascular adhesion molecules and inflammatory cytokines in HUVECs via Akt- and AMPK-dependent mechanisms. Mol Cell Endocrinol. 2015;405:25–34.
   PubMed Web of Science ®Google Scholar
• Björkegren JLM, Lusis AJ. Atherosclerosis: recent developments. Cell. 2022;185(10):1630–1645.
   PubMed Web of Science ®Google Scholar
• Lin P, Ji HH, Li YJ, Guo SD. Macrophage plasticity and atherosclerosis therapy. Front Mol Biosci. 2021;8:679797.
   PubMed Web of Science ®Google Scholar
• Brenner C, Franz WM, Kühlenthal S, et al. DPP-4 inhibition ameliorates atherosclerosis by priming monocytes into M2 macrophages. Int J Cardiol. 2015;199:163–169.
   PubMed Web of Science ®Google Scholar
• Wang H, Li Y, Zhang X, Xu Z, Zhou J, Shang W. DPP-4 inhibitor linagliptin ameliorates oxidized LDL-induced THP-1 macrophage foam cell formation and inflammation. Drug Des Devel Ther. 2020;14:3929–3940.
   PubMed Web of Science ®Google Scholar
• Dai Y, Dai D, Wang X, Ding Z, Mehta JL. DPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathway. Cardiovasc Drugs Ther. 2014;28(5):425–432.
   PubMed Web of Science ®Google Scholar
• Wiciński M, Górski K, Wódkiewicz E, Walczak M, Nowaczewska M, Malinowski B. Vasculoprotective effects of vildagliptin. focus on atherogenesis. Int J Mol Sci. 2020;21(7):2275.
   PubMed Web of Science ®Google Scholar
• Wang SC, Wang XY, Liu CT, et al. The dipeptidyl peptidase-4 inhibitor linagliptin ameliorates endothelial inflammation and microvascular thrombosis in a sepsis mouse model. Int J Mol Sci. 2022;23(6):3065.
   PubMed Web of Science ®Google Scholar
• Trzaskalski NA, Fadzeyeva E, Mulvihill EE. Dipeptidyl peptidase-4 at the interface between inflammation and metabolism. Clin Med Insights Endocrinol Diabetes. 2020;13:1179551420912972.
   Web of Science ®Google Scholar
• Morishita T, Uzui H, Ikeda H, et al. Effects of sitagliptin on the coronary flow reserve, circulating endothelial progenitor cells and stromal cell-derived factor-1alpha. Intern Med. 2019;58(19):2773–2781.
   PubMed Web of Science ®Google Scholar
• Fadini GP, Bonora BM, Cappellari R, et al. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101(2):748–756.
   PubMed Web of Science ®Google Scholar
• Moraes RM, Lima GM, Oliveira FE, et al. Exenatide and sitagliptin decrease interleukin 1β, matrix metalloproteinase 9, and nitric oxide synthase 2 gene expression but does not reduce alveolar bone loss in rats with periodontitis. J Periodontol. 2015;86(11):1287–1295.
   PubMed Web of Science ®Google Scholar
• Zhu E, Hu L, Wu H, et al. Dipeptidyl peptidase-4 regulates hematopoietic stem cell activation in response to chronic stress. J Am Heart Assoc. 2017;6(7):e006394.
   PubMed Web of Science ®Google Scholar
• Jakubiak GK, Pawlas N, Cieślar G, Stanek A. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int J Environ Res Public Health. 2021;18(22):11970.
   PubMed Web of Science ®Google Scholar
• Akita K, Isoda K, Shimada K, Daida H. Dipeptidyl-peptidase-4 inhibitor, alogliptin, attenuates arterial inflammation and neointimal formation after injury in low-density lipoprotein (LDL) receptor-deficient mice. J Am Heart Assoc. 2015;4(3):e001469.
   PubMed Web of Science ®Google Scholar
• Terawaki Y, Nomiyama T, Kawanami T, et al. Dipeptidyl peptidase-4 inhibitor linagliptin attenuates neointima formation after vascular injury. Cardiovasc Diabetol. 2014;13:154.
   PubMed Web of Science ®Google Scholar
• Jin X, Jin C, Nakamura K, et al. Increased dipeptidyl peptidase-4 accelerates chronic stress-related thrombosis in a mouse carotid artery model. J Hypertens. 2020;38(8):1504–1513.
   PubMed Web of Science ®Google Scholar
• Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a Report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2022;145(18):e895–e1032.
   PubMed Web of Science ®Google Scholar
• Zannad F, Rossignol P. Dipeptidyl peptidase-4 inhibitors and the risk of heart failure. Circulation. 2019;139(3):362–365.
   PubMed Web of Science ®Google Scholar
• Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2015;132(15):e198.
   PubMed Web of Science ®Google Scholar
• Poudyal H. Mechanisms for the cardiovascular effects of glucagon-like peptide-1. Acta Physiol. 2016;216(3):277–313.
   PubMed Web of Science ®Google Scholar
• Papazafiropoulou AK, Papanas N, Trikkalinou A, Fousteris E, Melidonis A. The oral dipeptidyl-peptidase-4 inhibitor sitagliptin increases circulating levels of stromal-derived factor-1 alpha. Exp Clin Endocrinol Diabetes. 2018;126(6):367–370.
   PubMed Web of Science ®Google Scholar
• Zhong J, Rajagopalan S. Dipeptidyl peptidase-4 regulation of SDF-1/CXCR4 axis: implications for cardiovascular disease. Front Immunol. 2015;6:477.
   PubMed Web of Science ®Google Scholar
• Whittam AJ, Maan ZN, Duscher D, et al. Small molecule inhibition of dipeptidyl peptidase-4 enhances bone marrow progenitor cell function and angiogenesis in diabetic wounds. Transl Res. 2019;205:51–63.
   PubMed Web of Science ®Google Scholar
• González A, Schelbert EB, Díez J, Butler J. Myocardial interstitial fibrosis in heart failure: biological and translational perspectives. J Am Coll Cardiol. 2018;71(15):1696–1706.
   PubMed Web of Science ®Google Scholar
• López B, Ravassa S, Moreno MU, et al. Diffuse myocardial fibrosis: mechanisms, diagnosis and therapeutic approaches. Nat Rev Cardiol. 2021;18(7):479–498.
   PubMed Web of Science ®Google Scholar
• Hirose M, Takano H, Hasegawa H, et al. The effects of dipeptidyl peptidase-4 on cardiac fibrosis in pressure overload-induced heart failure. J Pharmacol Sci. 2017;135(4):164–173.
   PubMed Web of Science ®Google Scholar
• Hocher B, Reichetzeder C, Alter ML. Renal and cardiac effects of DPP4 inhibitors--from preclinical development to clinical research. Kidney Blood Press Res. 2012;36(1):65–84.
   PubMed Web of Science ®Google Scholar
• Ames MK, Atkins CE, Pitt B. The renin-angiotensin-aldosterone system and its suppression. J Vet Intern Med. 2019;33(2):363–382.
   PubMed Web of Science ®Google Scholar
• Garcia-Garduño TC, Padilla-Gutierrez JR, Cambrón-Mora D, Valle Y. RAAS: a convergent player in ischemic heart failure and cancer. Int J Mol Sci. 2021;22(13):7106.
   PubMed Web of Science ®Google Scholar